Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth

The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs.

10/20/2026, 4:57 AM • GlobeNewswire

Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million

Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.

10/15/2026, 11:00 AM • GlobeNewswire

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

10/06/2026, 4:54 AM • GlobeNewswire

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

10/05/2026, 6:45 AM • GlobeNewswire

Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight

The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region.

10/01/2026, 1:00 PM • GlobeNewswire

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.

09/30/2026, 1:15 PM • The Motley Fool

Where Will Illumina Stock Be in 5 Years If Its AI Bet Pays Off?

Illumina is developing an AI strategy centered on biological data from its sequencing technology. The company's initiatives, including the Billion Cell Atlas and expanded drugmaker partnerships, could create a new growth engine if it successfully converts its scientific advantages into recurring commercial revenue.

09/29/2026, 8:45 PM • The Motley Fool

The Market Just Told You Which Layer Of AI Biology It Is Paying For

Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.

09/03/2026, 2:10 PM • GlobeNewswire

Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with Confidence

ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

08/07/2026, 5:56 AM • GlobeNewswire

AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine

Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.

08/06/2026, 10:52 AM • GlobeNewswire

Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?

Grail's stock has declined from a record high of $116.06 to under $70 following a failed NHS England trial for its Galleri blood cancer test. However, the company continues generating revenue ($147M in 2025) through direct-to-consumer sales and is expected to grow to $281M by 2028. Despite the setback, analysts recommend holding the stock as an FDA approval could significantly boost growth prospects.

08/01/2026, 1:08 PM • The Motley Fool

Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

07/24/2026, 9:30 AM • GlobeNewswire

Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate

The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.

07/17/2026, 6:44 AM • GlobeNewswire

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

07/17/2026, 5:54 AM • GlobeNewswire

Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR

The global environmental DNA (eDNA) market is expected to grow at a CAGR of 10.2% from 2026 to 2031, driven by non-invasive species detection methods, stricter environmental regulations, and increasing demand for ecosystem health monitoring. North America leads the market with advanced research infrastructure and strong public-private collaborations, while air sampling and climate change impact assessment segments show particularly strong growth potential.

07/06/2026, 4:49 AM • GlobeNewswire